Biosimilar Kanjinti Gets FDA Approval for Breast, Gastric Cancer
Kanjinti, a HER2/neu receptor antagonist, is indicated for adjuvant treatment of HER2-overexpressing node positive or node negative.
Gastric Cancer
Pembrolizumab Found as Effective as Chemotherapy for Gastric Cancers
Initial therapy with pembrolizumab may result in comparable overall survival as standard chemotherapy in patients with PD-L1–positive, HER2-negative, advanced gastric or gastroesophageal junction cancer.
Docetaxel Plus S-1 Postoperative Chemotherapy in Stage III Gastric Cancer Found to Improve RFS
Based on an interim analysis showing efficacy for postoperative docetaxel plus S-1 compared with S-1 alone, this trial in stage III gastric cancer was closed early.
Distinct Clinical and Molecular Features Linked to Early-Onset Colorectal Cancer
Some patients with colorectal cancer are more likely to have disease characterized by a high frequency of mutations, microsatellite instability, and strong immune activation.
Differences in the Diagnosis, Management, and Outcomes of Hispanic Patients With Gastric Cancer Revealed
A retrospective study of patients with gastric cancer in the United States showed differences in patient- and disease-related characteristics, as well as different frequencies of staging laparoscopy, treatment/surgical approaches, and specific clinical outcomes, for those of Hispanic compared with non-Hispanic ethnicity. This study was published in the Journal of Surgical Oncology. In the US, the incidence of gastric…
Lonsurf Gains Metastatic Gastric Cancer Indication
The Food and Drug Administration has approved Lonsurf (trifluridine and tipiracil; Taiho Oncology) for the treatment of adult patients with metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma previously treated with at least 2 prior lines of chemotherapy that included a fluoropyrimidine, a platinum, either a taxane or irinotecan, and if appropriate, HER2/neu-targeted therapy. The approval was based…
MET Inhibitor as a Monotherapy in GI Cancers: Unlikely Beneficial
The study was halted when patient response rates were lower than those seen across a similar trial involving the drug.
Trifluridine/Tipiracil Improves OS, PFS in Metastatic Gastric Cancer
Trifluridine plus tipiracil may be an effective treatment option for patients with heavily pretreated metastatic gastric cancer, according to presenters at ESMO 2018.
Pembrolizumab Did Not Improve PFS or OS Compared With Paclitaxel in Relapsed Gastric or Gastroesophageal Junction Cancer
Results from the KEYNOTE-061 were presented at ESMO World GI 2018.
Dendritic Cell Vaccine Plus Salvage Chemotherapy Active in Gastric Cancer
A recent trial evaluated the safety and efficacy of a DC vaccine combined with salvage chemotherapy.
Next post in ESMO GI 2018
